Wake-Promoting Pharmacotherapy for Psychiatric Disorders

@article{DellOsso2014WakePromotingPF,
  title={Wake-Promoting Pharmacotherapy for Psychiatric Disorders},
  author={Bernardo Dell’Osso and Cristina Dobrea and Laura Cremaschi and Chiara Arici and Alfredo Carlo Altamura},
  journal={Current Psychiatry Reports},
  year={2014},
  volume={16},
  pages={1-11}
}
Medications promoting wakefulness are currently used in psychopharmacology in different contexts and with different objectives. In particular, they may be used for the treatment of syndromes that primarily show significant impairment in alertness/wakefulness (e.g., excessive sleepiness and other sleep disorders) as well as for the symptomatic treatment of different neuropsychiatric disorders that, in turn, are not exclusively characterized by sleep-wake disturbances (like mood disorders, for… Expand
Methylphenidate-induced psychosis in a young antipsychotic-naïve female patient
TLDR
A case report of MPD-induced psychosis in a 31-year-old, antipsychotic-naïve patient is presented and careful evaluation is recommended each time MPD treatment is initiated. Expand
Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects
TLDR
Modafinil is a nonamphetamine nootropic drug with an increasingly therapeutic interest due to its different sites of action and behavioral effects in comparison to cocaine or amphetamine, and its psychotropic and cognitive effects are also attractive in several other pathologies and conditions that affect sleep structure, induce fatigue and lethargy, and impair cognitive abilities. Expand
ADHD With Comorbid Bipolar Disorders: A Systematic Review of Neurobiological, Clinical And Pharmacological Aspects Across The Lifespan.
TLDR
A systematic review of the scientific literature on the neurobiological, clinical features and current pharmacological management of ADHD comorbid with BDs across the entire lifespan, with a major focus on the adulthood. Expand
Pharmacological profiling of zebrafish behavior using chemical and genetic classification of sleep-wake modifiers
Sleep-wake states are impaired in various neurological disorders. Impairment of sleep-wake states can be an early condition that exacerbates these disorders. Therefore, treating sleep-wakeExpand
The Effects of the Atypical Dopamine Uptake Inhibitor CE-158 on Extracellular Dopamine in the Nucleus Accumbens
Major Depressive Disorder (MDD) is characterized by symptoms such as cognitive dysfunctions, inflammatory changes, and motivational symptoms such as amotivation, fatigue, and anergia. While depressedExpand
Lifetime evolution of ADHD treatment
TLDR
A naturalistic review to review and comment on the available literature of ADHD treatment across the lifespan finds stimulants are endowed of a prompt efficacy and safety, whilst non-stimulants are useful when a substance abuse history is detected. Expand
Psikiyatrik Bozukluklarda Modafinil Kullanimiof Modafinil in Psychiatric Disorders
TLDR
The aim of this article is to review the literature on clinical use of modafinil in psychiatric disorders and show initial promise for a variety of off-label indications in psychiatry, including bipolar disorder, attention-deficit/hyperactivity disorder, and schizophrenia. Expand
Possible use of a H3R antagonist for the management of nonmotor symptoms in the Q175 mouse model of Huntington's disease
TLDR
It is demonstrated that daily treatment with GSK189254 improved several behavioral measures in the Q175 mice including strengthening activity rhythms, cognitive performance and mood as measured by the tail suspension test and drugs targeting the H3R system may show benefits as cognitive enhancers in the management of HD. Expand
Differential effect of modafinil on impulsivity, attention and motor activity in preadolescent rats prenatally treated with alcohol
TLDR
The data suggest that the main target of modafinil is the DA system, which has an important role in impulsive behavior and hyperactivity in male Wistar rats treated with prenatal alcohol. Expand
Activation of the GABAergic Parafacial Zone Maintains Sleep and Counteracts the Wake-Promoting Action of the Psychostimulants Armodafinil and Caffeine
TLDR
Results suggest that PZVgat neurons represent a key cell population for SWS induction and maintenance and armodafinil cannot exert its wake-promoting effects when PZvgat neurons are activated, intimating a possible shared circuit/molecular basis for mechanism of action. Expand
...
1
2
...

References

SHOWING 1-10 OF 100 REFERENCES
Assessing the Roles of Stimulants/Stimulant-like Drugs and Dopamine-agonists in the Treatment of Bipolar Depression
TLDR
Findings from reviewed studies suggested that pro-dopaminergic compounds, such as pramipexole and stimulants/stimulant-like agents, deserve consideration as adjunctive therapies in bipolar depressed patients, at least in some subgroups of patients. Expand
Current and Emerging Options for the Drug Treatment of Narcolepsy
TLDR
Night-time administration of a short-acting sedative, γ-hydroxybutyrate (sodium oxybate), has been used for the treatment for EDS and cataplexy and it is expected that more pathophysiology-based treatments will be available in the near future. Expand
The use of stimulant medications for non-core aspects of ADHD and in other disorders
TLDR
The evidence pertaining to the use of methylphenidate, dexamphetamine and related amphetamine salts, the prodrug lisdexamfetamine and modafinil for the management of comorbid ADHD and non-ADHD indications is reviewed. Expand
Approved and Investigational Uses of Modafinil
TLDR
Modafinil had a substantial placebo effect on outcomes such as fatigue, excessive sleepiness and depression in patients with traumatic brain injury, major depressive disorder, schizophrenia, post-polio fatigue and multiple sclerosis; however, it did not provide any benefit greater than placebo. Expand
Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation.
TLDR
The present case series suggests that adjunctive stimulants may be a reasonable therapeutic option for treating residual depression and medication-induced sedation in some patients with bipolar disorder. Expand
Orexin (Hypocretin) Receptor Agonists and Antagonists for Treatment of Sleep Disorders
TLDR
The discovery of a critical role played by the orexin system in the regulation of sleep/wakefulness has opened the door of a new era for sleep medicine. Expand
Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls
TLDR
The progress associated with therapeutic attempts to restore orexin system function and treat neuropsychiatric conditions such as addiction, depression and anxiety are discussed. Expand
Neurochemical Consequences of Dysphoric State During Amphetamine Withdrawal in Animal Models: A Review
TLDR
This review focuses on the molecular aspects of AM PH withdrawal as indexed by neurochemical parameters under a variety of injection regimens in rodent models which exhibit significant phenotypic features relevant to the syndromes of AMPH withdrawal in humans. Expand
Cardiovascular Effects of Methylphenidate, Amphetamines and Atomoxetine in the Treatment of Attention-Deficit Hyperactivity Disorder
TLDR
The cardiovascular safety of drugs such as methylphenidate, amphetamines and atomoxetine is examined with regard to effects on blood pressure, heart rate, ECG parameters and the risk of sudden death. Expand
An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy.
TLDR
In patients with MDD who experience sedation as a side effect of antidepressant therapy, adjunctive modafinil improved wakefulness and reduced fatigue and modafInil plus SSRIs also improved mood and quality of life. Expand
...
1
2
3
4
5
...